<DOC>
	<DOCNO>NCT00838110</DOCNO>
	<brief_summary>This multi-center , randomize , double-blind placebo-controlled safety study conduct 2 study cohort . In Cohort 1 , subject Alzheimer 's disease ( n=250 ) receive Dimebon 20 mg placebo TID 26 week . In Cohort 2 AD subject ( n=500 ) treat Dimebon 20 mg placebo TID 12 week After completion randomize portion study , subject Cohorts opportunity enroll Dimebon open label extension study .</brief_summary>
	<brief_title>A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Diagnosis Alzheimer 's Disease . MMSE 1226 inclusive . If exist antidementia therapy , stable dose antidementia therapy ( cholinesterase inhibitor and/or memantine ) least 60 day prior dose study . If take exist antidementia therapy , receive therapy cholinesterase inhibitor and/or memantine within 60 day prior dose study . Have major structural brain disease ( e.g. , ischemic infarct , subdural hematoma , hemorrhage , hydrocephalus , brain tumor , multiple subcortical ischemic lesion , single lesion critical region [ e.g. , thalamus , hippocampus ] ) . Have major medical illness unstable medical condition within six month screen may interfere patient 's ability comply study procedure abide study restriction . Have stable dose antidementia therapy least 60 day prior dose intend start antidementia therapy double blind portion study . Reside nursing home assist care facility need 24hour care supervision .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Alzheimer 's Disease</keyword>
	<keyword>Dimebon</keyword>
	<keyword>Safety</keyword>
	<keyword>Tolerability</keyword>
</DOC>